Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.

Leukemia
Hartmut GoldschmidtGerman Myeloma Multicenter Group (GMMG)

Abstract

The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase III, multicenter trial randomized patients with 1st-3rd relapse of multiple myeloma (MM) to a transplant arm (n = 139) consisting of 3 Rd (lenalidomide 25 mg, day 1-21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles) reinduction cycles, sHDCT (melphalan 200 mg/m2), ASCT, and lenalidomide maintenance (10 mg/day) or to a control arm (n = 138) of continuous Rd. Median PFS was 20.7 months in the transplant and 18.8 months in the control arm (HR 0.87; 95% CI 0.65-1.16; p = 0.34). Median OS was not reached in the transplant and 62.7 months in the control arm (HR 0.81; 95% CI 0.52-1.28; p = 0.37). Forty-one patients (29%) did not receive the assigned sHDCT/ASCT mainly due to early disease progression, adverse events, and withdrawal of consent. Multivariate landmark analyses from the time of sHDCT showed superior PFS and OS (p = 0.0087/0.0057) in patients who received sHDCT/ASCT. Incorporation of sHDCT/ASCT into relapse treatment with Rd was feasible in 71% of patients and d...Continue Reading

References

May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Nov 23, 2007·The New England Journal of Medicine·Donna M WeberUNKNOWN Multiple Myeloma (009) Study Investigators
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker
May 11, 2012·The New England Journal of Medicine·Michel AttalUNKNOWN IFM Investigators
Oct 12, 2013·British Journal of Haematology·Djordje Atanackovic, Georgia Schilling
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Apr 28, 2016·The New England Journal of Medicine·Philippe MoreauUNKNOWN TOURMALINE-MM1 Study Group
Oct 6, 2016·The New England Journal of Medicine·Meletios A DimopoulosUNKNOWN POLLUX Investigators
Feb 12, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·Shaji K KumarRashmi Kumar
Apr 6, 2017·The New England Journal of Medicine·Michel AttalUNKNOWN IFM 2009 Study
Jul 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip L McCarthyMichel Attal

❮ Previous
Next ❯

Citations

Feb 8, 2021·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Jun 3, 2021·Cancers·Fredrik Schjesvold, Albert Oriol
Jun 25, 2021·Bone Marrow Transplantation·Christopher LemieuxSurbhi Sidana
Jun 16, 2021·European Journal of Haematology·Donna E ReeceChristopher P Venner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.